W M Mackin
W M Mackin
XOMA is developing Neuprex, an injectable recombinant protein fragment (rBPI-21) of the naturally-occurring bactericidal/permeability increasing (BPI) protein, for serious infections and infectious complications of trauma and surgery. Neupr...
Macrulin Cortecs Ltd [0.03%]
麦克鲁林柯特克斯有限公司
J Luo
J Luo
Cortecs is developing Macrulin, a Macrosol system for the oral delivery of insulin, for the potential treatment of non-insulin dependent diabetes. The compound is in phase II clinical development [272442], [276928]. Final analysis of result...
B J Dong
B J Dong
Efavirenz is the lead compound of a series of benzoxazinones originally developed by DuPont Merck. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the potential treatment of viral infections, including H...
H Geerts
H Geerts
AIT-082 (an analog of hypoxanthine) is an orally-active nerve growth factor (NGF) agonist under development by NeoTherapeutics as a potential treatment for Alzheimer's disease (AD), stroke and motor neuron disease. A phase II safety and eff...
Endothelial ATP-sensitive potassium channels: a new therapeutic target in cardiovascular medicine? [0.03%]
心血管医学中的新治疗目标：内皮细胞ATP敏感型钾通道？
U Langheinrich
U Langheinrich
Recent electrophysiological studies have demonstrated convincingly that ATP-sensitive potassium channels (KATP) are expressed in macro- and microvascular endothelial cells from heart and brain. Several reports have indirectly demonstrated t...
Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization [0.03%]
基于质粒DNA的 alphavirus 表达载体的核酸免疫
D A Driver,J M Polo,B A Belli et al.
D A Driver et al.
Alphavirus-derived vectors are being developed for vaccine, gene therapy and recombinant protein production applications, based in part on observations of transient, high level expression of heterologous genes in eukaryotic cells. Efficient...
Inhibitors of apoptosis, APP processing and prostaglandin formation: disease modifying drugs for Alzheimer's disease? [0.03%]
凋亡抑制剂、APP代谢和前列腺素形成的调节剂能成为治疗阿尔茨海默病的疾病改良药物吗？
P L Wood
P L Wood
There is currently a vast array of compounds in clinical trials dealing with the cholinergic deficits characteristic of Alzheimer's disease (AD). There are already many reviews addressing this approach which, to date, has yielded only minim...
V Subbarao,J Phillips,G A Stouffer
V Subbarao
Glycoprotein IIb/IIIa inhibitors are potent platelet inhibitors that are beneficial in the treatment of patients undergoing high-risk percutaneous interventions and in patients with unstable angina or non-Q-wave myocardial infarction. Bleed...
Nucleotides and their receptors in the nervous system. 1-2 August 1998, Leipzig, Germany [0.03%]
核苷酸及其神经系统受体会议综述(德国莱比锡,1998年8月1~2日)
M F Jarvis,M Williams
M F Jarvis
This meeting was the second in four months to cover the role of P2 purinoreceptors in tissue function and pathophysiology, the previous being the Sixth International Symposium on Adenosine and Adenine Nucleotides held in Ferrara, Italy in M...
Receptor mechanisms: principles of agonism. 23-25 July 1998, Merano, Italy [0.03%]
受体机制：激动剂原理会议纪要。1998年7月23日～25日，意大利梅拉诺
H Gronemeyer
H Gronemeyer
This conference was the first of a series of biannual meetings covering important aspects of receptor behavior and was held as a satellite to the IUPHAR Congress in Munich. Among its aims were the definition and mechanisms of efficacy at st...